Nick Colangelo has become senior vice president of corporate development and operations at Oscient Pharmaceuticals, the Waltham, Mass.-based company said yesterday. He comes to Oscient from Eli Lilly, where he was a managing director of Lilly Ventures. Colangelo holds a law degree from the Duke University School of Law and a bachelor's degree from the State University of New York at Buffalo.
Tina Nova has joined the board of directors of Heska, a veterinary diagnostic products manufacturer, the company said last week. Nova is president, CEO, director, and co-founder of Genoptix. She served as president and COO of Nanogen from 1994 to 2000. Nova holds a PhD in biochemistry from the
David Ichikawa has become senior vice president for business development at Sangamo BioSciences, the Point Richmond, Calif.-based company said yesterday. Most recently, he was chief business officer of Sagres Discovery. Prior to that, he held several positions with Chiron.
Michael Treble has become CEO of the Ibis program of Isis Pharmaceuticals, the company said yesterday. Ibis plans to develop a biosensor to identify infectious organisms. Prior to joining
In addition, Richard DiMarchi has joined the board of directors of Isis, the company said last month. He is a professor of biomolecular science at
Bryan Koontz has joined Tripos as vice president of corporate development for discovery informatics as part of the recent acquisition of Optive Research by Tripos, the St. Louis-based company said today. He is the former CEO of Optive. In addition, several scientists and developers from Optive have joined Tripos's Discovery Informatics business and will continue to work out of
Tony Colangelo has become vice president of North American sales and Olle Landström vice president of engineering for Spotfire, the Somerville, Mass.-based company said today. The company has also added several new field representatives in all regions. Colangelo joins Spotfire from Bristol Technologies, where he led the field sales team. Landström, who will be based in
Deborah Smeltzer has become CFO and vice president for operations of Dynavax, the Berkeley, Calif.-based company said today. She joins Dynavax from Applied Biosystems, where she was vice president and general manager of the company's genetic analysis business. Prior to that, she was CFO and vice president of Genset, a French genomics company. Smeltzer holds an MBA from the Stanford University Graduate School of Business and an MS in medical microbiology from the
Allen Ruzycki has joined Phyton Biotech, a subsidiary of Fort Worth, Texas-based DFB Pharmaceuticals, as director of finance and administration, the company said last week. Most recently, he was acting director of finance for an unnamed privately held company, Phyton said. He has also been employed by Nabisco, Fisher Scientific, Poly Chrome, and BASF Corporation. Ruzycki holds a BA in finance from
Philip Vorwald has become vice president of worldwide sales for Guava Technologies, the Hayward, Calif.-based company said on Monday. Recently, he was managing director of Delphi Medical Systems. Prior to that, he held several positions at Becton Dickinson Biosciences. Vorwald holds an MS from the Medical College of Virginia and a BS from the
Frank Baldino has joined the board of directors of Pennsylvania Bio, the organization said last week. He is the CEO, chairman, and founder of Cephalon. Baldino holds a PhD in pharmacology from
Merrilyn Datta has become the new director of RNAi in the functional genomics business segment of Invitrogen, GenomeWeb News has learned. She replaces Nikki Zahl, who has become director of genomics at Invitrogen. She was previously marketing manager for RNAi at the company, and before that marketing manager for cloning and gene expression. Datta holds a PhD from
EMBL has established a Bioinformatics Advisory Committee. Members of the committee include Søren Brunak, chairman of the Technical University of Denmark; John Sulston of the Wellcome Trust Sanger Institute; Anna Tramontano of the University of Rome "La Sapienza;" Martin Vingron of the Max Planck Institute for Molecular Genetics; and Gunnar von Heijne of Stockholm University.